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ABSTRACT
Inborn errors of liver metabolism are frequent causes of morbidity and mortality 
especially in children. For several of these diseases, treatment approaches depend on 
manipulation of the affected metabolic pathway by diet, drugs, vitamin cofactors, enzyme 
induction, end-product replacement, and alternative pathway activation. Unfortunately, 
these approaches often remain unsatisfactory especially in the face of illness or catabolism. 
Ideally, transfer of the normal genes in the liver cells that are defective might restore the 
metabolic function. The goal of my PhD thesis was to develop gene-based therapeutic 
strategies to correct a life-threatening inborn error of liver metabolism, Crigler-Najjar 
syndrome type I (CNI). CNI is a severe inborn error of bilirubin metabolism due to 
mutations of the uridine diphospho-glucuronosyl transferase 1A1 (UGT1A1) gene. Affected 
patients have elevations of serum bilirubin, and they have to spend extended hours under 
bilirubin lights throughout childhood and adolescence. Despite this therapy, they remain at 
risk of brain damage when intercurrent infections may increase production of bilirubin 
above that which can be controlled by the bilirubin light therapy. Thus, patients with CNI 
often are advised to consider liver transplantation. Therefore, alternative therapies are 
highly needed to overcome the mortality and morbidity associated with transplantation 
procedure, and risks of life-long immunosuppression. Gene therapy has the potential to 
provide a definitive cure for patient with CNI. My studies have focused on the development 
of gene therapy strategies for this disease. First, I investigated in Gunn rats, the animal 
model for CNI, the efficacy of adeno-associated viral (AAV) vector-mediated muscle- 
directed gene therapy and I found that serotype 1 AAV vector expressing UGT1A1 resulted 
in expression of UGT1A1 protein and functionally active enzyme in injected muscles, and a
4
50% reduction in serum bilirubin levels for at least 1 year post-injection. Taken together, 
these data show that clinically relevant and sustained reduction of serum bilirubin levels 
can be achieved by simple and safe intramuscular injections.
Following initial problems with intravenous injections of AAV2 vector, a major success 
has been achieved with AAV2/8 vectors for liver-directed gene therapy of hemophilia. 
Encouraged by these results and by the possibility of achieving full correction of the 
hyperbilirubinemia with systemic delivery, next I focused on the design and optimization of 
an AAV2/8 vector for liver-directed gene therapy of CNI. I generated multiple expression 
cassettes expressing the UGT1A1 gene inserted into the AAV2/8 vectors for in vivo testing. 
The results of these studies showed that AAV2/8 vector with codon optimized UGT1A1 
gene under the control of the hepatocyte-specific LP1 promoter resulted in improved and 
sustained correction of hyperbilirubinemia in Gunn rats. Taken together, these data 
demonstrate the development of an optimal expression cassette for liver-directed gene 
therapy of CNI and form the preclinical basis for the development of a gene therapy trial 
for this severe disorder.
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1. BACKGROUND
1.1 Inborn errors of metabolism
The term “inborn errors of metabolism (IEM)” was coined by Archibald Garrod in 
1908 and is used to describe disorders caused by a deficiency of enzyme catalysis or an 
enzyme that facilitates the transport of biological substances across membranes. IEM 
comprise a group of disorders in which a single gene defect causes a clinically significant 
block in a metabolic pathway that results either in accumulation of substrate upstream 
enzymatic block or deficiency of the downstream product. Over 200 of these disorders have 
been identified and a significant proportion of them present clinically in the neonatal period 
or in early infancy.
The liver is a key organ for most metabolic pathways, and therefore, numerous 
metabolic inherited diseases originate from defects in this organ (Nguyen and Ferry 
2004). For most conditions, treatment approaches depend on manipulation of the metabolic 
pathway by diet, drugs, vitamin cofactors, enzyme induction, end-product replacement, and 
alternative pathway activation. Unfortunately, these approaches are often unsatisfactory 
particularly when the flux through the affected pathway increases in the face of illness or 
catabolism (Brunetti-Pierri and Lee 2005). When such relatively simple measures are 
insufficient to maintain health, exogenous supply of the deficient enzyme, known as 
enzyme replacement therapy (ERT) can provide quite effective treatment for the enzyme 
deficiencies (Ellor et al. 2008). For example, patients with lysosomal storage disorders 
are able to benefit from this type of supplementation. Nevertheless, even when ERT is 
effective, it does not provide a cure from the disorder, and the patient is dependent on
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lifelong intravenous infusion of the drug. For most metabolic disorders, the only permanent 
treatment available is orthotopic liver transplantation (OLT) (STARZL 1978). A healthy 
donor liver will restore endogenous enzyme production, effectively repairing the metabolic 
disorder. However, the transplant procedure is invasive and is associated with high 
mortality and morbidity. Moreover, OLT requires lifelong immunosuppression that has its 
own risks. In addition, limited donor organ availability, risks of surgical complications and 
rejection are major limitations of this treatment. Therefore, it is important to develop 
alternative treatments to OLT.
Hepatocyte transplantation is an attractive alternative because of the limited 
invasiveness of the procedure. However, this transplant procedure has several limitations, 
including poor engraftment and short term efficacy. Moreover, this approach will still 
require lifelong immunosuppression.
Gene replacement therapy has the great potential of providing a definitive cure for 
patients affected with IEMs.
1.2 Disease candidates for liver-directed gene therapy
An ideal candidate for gene therapy is a disease in which there is an immediate and 
simple measure of efficacy, in which the only alternative therapy is liver transplantation, 
and a disorder that benefits from low expression levels of the defective enzyme. How much 
correction is needed for phenotypic correction ultimately depends on the magnitude of the 
metabolic flux through the biochemical pathway at the cellular and tissue levels. This is 
determined by the capacity of the biochemical pathway to be up-regulated by
11
overexpression of various rate-limiting and non rate-limiting steps and by the degree of 
cellular autonomy of the target enzyme (Brunetti-Pierri and Lee 2005). The scale of 
metabolic correction has been determined indirectly by animal gene transfer studies 
(Figure 1). In general, disorders that are non-cell autonomous, such as hemophilia A and B 
or the mucopolysaccharidoses (MPS), require less transduction of the liver than cell 
autonomous defects such as the urea cycle disorders. This is partially due to the potential of 
cross-correction when secreted proteins in the MPS act distally either outside or inside the 
target cells. At the same time, the magnitude of metabolic flux is also critical in 
determining the percentage of liver transduction required for phenotypic correction. 
Diseases due to enzymatic deficiencies may generally require higher percentage of 
correction compared to diseases such as hemophilia (Brunetti-Pierri and Lee 2005). 
Some of the candidate disorders for liver-directed gene therapy are listed in Table 1. 
Homozygous familiar hypercholesterolemia (FH) is an attractive disorder but there is 
significant risk of atherosclerosis with LDL-receptor levels that are 50% of normal. It is 
likely that relatively low levels of expression would achieve some lowering of cholesterol 
in homozygous FH, and this might provide some measure of efficacy. However, much 
higher levels of expression are likely needed to obtain optimal benefit in homozygous FH. 
Glycogen storage disease (GSD-la) also are likely required to obtain full phenotypic 
correction although a smaller percentage may be sufficient for correction of the 
hypoglycemia. Ornithine transcarbamylase (OTC) deficiency is an alternative that might be 
considered, particularly in males otherwise scheduled for liver transplantation.
However, measurement of efficacy in OTC deficiency is somewhat complicated since it 
depends on dietary intake of protein and other variables.
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1-5% 5-10% 20-30% >30%
Hemophilia/ MPS Urea Cycle Lipoproteins
Crigler-Najjar
Figure 1. Percentage of hepatocytes expressing the normal gene required for 
phenotypic correction of different liver metabolic disorders (MPS=mucopolysaccharidoses) 
(Brunetti-P ierri and Lee 2005).
Crigler-Najjar type 1 Very rare Liver
transplant
Yes Bilirubin levels
GSD-la More
feasible
Liver
transplant
Yes Glucose levels
Hemophilias 
(A and B)
More
feasible
Protein
replacement
Yes Factor levels
FH (homozygous) Very rare Liver
transplant
Likely need high 
expression
LDL levels
OTC deficiency More
feasible
Liver
transplant
Partially More difficult
Table 1. Candidate disorders for liver-directed gene therapy.
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Crigler-Najjar syndrome (CN) type I is an excellent candidate disease for gene therapy 
for several reasons:
it is a life-threatening disease requiring cumbersome treatment with 
phototherapy or liver transplantation (Strauss et al. 2006), and the risk/benefit 
ratio is favorable;
- the underlying defect is well characterized at the biochemical and molecular 
levels;
- there is evidence that low levels o f gene expression will ameliorate the 
hyperbilirubinemia, as suggested by hepatocyte transplantation studies 
(CHOWDHURY et al 1998) and because patients with CN type II have marked 
reduction but not total loss of enzyme activity, and their disease is much milder 
than type I;
- the outcomes of the experimental therapy can be easily monitored by measuring 
bilirubin in serum;
- it does not affect liver architecture;
- an animal model, the Gunn rat, is available to investigate experimental therapies 
(CHOWDHURY et al. 1993).
CN type I is also attractive for gene therapy because UGT1A1 can be produced from 
skeletal muscle other than liver, its natural production site, and still retain the ability to 
transform bilirubin into water-soluble derivatives (Danko et al. 2004; JiA and Danko  
2005a).
The biggest negative of CN is the relative rarity of patients. The exact prevalence of 
CN is unknown but it is estimated to be as low as 1 case in 1 million live births. In some
15
populations (for example in from North Africa or the Amish and Mennonites) its 
prevalence is much higher.
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2. INTRODUCTION
2.1 Crigler-Najjar Syndrome
In 1952, Crigler and Najjar first described a syndrome presenting with severe, 
chronic hyperbilirubinemia (Crigler and Najjar 1952). CN (MIM 21880) is an autosomal 
recessive disorder presenting with non-hemolytic unconjugated hyperbilirubinemia. The 
disease is due to mutations (deletions, insertions, missense, nonsense, and splicing 
mutations) in the bilirubin-uridinediphosphoglucuronate glucuronosyltransferase 
(UGT1A1) gene on chromosome 2 encoding the hepatic enzyme uridine diphosphate 
glucuronyltransferase (UDPGT) which catalyzes the glucuronidation of bilirubin. This 
reaction is an essential step in excretion of bilirubin into the bile.
Two clinical forms of this syndrome have been described (Table 2): the more 
severe CN type I is characterized by high levels of serum unconjugated bilirubin (greater 
than 340 pM or 7-28 mg/dl, while the normal range is 0.2-1.0 mg/dl) owing to the nearly 
absence of UGT1A1 enzyme activity; and the milder CN type II with decreased UGT1A1 
enzymatic activity that presents unconjugated serum bilirubin levels in the range of 60-340 
pM (or 3-20 mg/dl). Mutations in the promoter of the UGT1A1 gene are responsible for 
Gilbert syndrome, a common benign condition with mild, unconjugated hyperbilirubinemia 
(serum bilirubin levels are of 60 pM or below) that affects approximately 5% of the 
population (BOSMA et al 1995).
Besides the levels of serum bilirubin, the difference between CN type I and II is 
based on clinical demonstration of efficacy of phenobarbital: in CN type I, the 
hyperbilirubinemia is not affected by the drug, whereas phenobarbital induces a rapid 
decline of serum bilirubin in CN type II.
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Crigler-Najjar Crigler-Najjar Gilbert Syndrom e 
Syndrom e Type I Syndrom e Type II
Histology of the liver Normal Normal Normal
Serum bilirubin 
concentration
20-50  m g /d l <20 m g/d l Usually < 3 m g/d l
Hepatic UGT activity A bsen t M arkedly  red u ced Reduced
Effect o f phenobarbital 
on serum bilirubin
N one Reduction Reduction
M ode o f inheritance A utosom al
recessive
A utosom al
recessive
A utosom al
recessive
Prevalence Rare Rare C om m on
Prognosis Kernicterus, 
unless vigorously 
t r e a t e d
Usualy benign, 
kern ic te rus  occurs 
rarely
Benign
Table 2. Differences between Crigler-Najjar syndrome type I and II and Gilbert syndrome.
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The reduction of hyperbilirubinemia induced by phenobarbital depends upon generalized 
induction of liver enzymes including UDPGT.
Patients with CN type I have elevated serum bilirubin levels that are refractory to 
phenobarbital treatment. The increase of serum bilirubin can be life-threatening and to 
maintain serum bilirubin below the threshold resulting in brain damage, affected patients 
generally sleep and spend extended hours under the visible blue lights throughout 
childhood and adolescence (Cremer et al 1958). Despite this therapy, they remain at risk 
of brain damage when intercurrent infections increase the production of bilirubin above 
levels that can be controlled by phototherapy (Strauss et al. 2006). In addition, the 
amount of time required under bilirubin lights tends to increase with age as there is a 
change in ratio of body surface area to body mass (CREMER et al. 1958). Thus, patients with 
CN type I are often advised to consider liver transplantation, most frequently in the range of 
18-25 years of age.
2.2 Bilirubin
Bilirubin is the normal breakdown product of the protoporphyrin portion of the 
heme group of proteins such as hemoglobin, myoglobin, and cytochrome P-450. An 
individual with normal human metabolism generates 250-400 mg/day of bilirubin through 
the breakdown of these hemoproteins (IYANAGI et al. 1998). The first step in the 
degradation of the heme group to bilirubin is cleavage of the a-methene bridge of heme to 
form biliverdin (Saito and Itano 1982). This reaction is catalyzed by microsomal the 
heme oxygenase (HO) that requires O2 and NADPH. Biliverdin is then reduced to bilirubin 
by the cytosolic biliverdin reductases which require NADH or NADPH (Figure 2).
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BilirubinHeme
NADP
+302 \  
5NADPH Biliverdin
reductase
Heme
oxygenase
NADPHCO
Biliverdin
Figure 2. Enzyme-catalyzed degradation of heme. Heme degradation begins by 
heme oxygenase-catalysed oxidation of the a-bridge carbon of heme, which is converted 
to CO, leading to opening of the tetrapyrrole ring and release of the iron. The resulting 
biliverdin molecules are next reduced to bilirubin by cytosolic biliverdin reductase.
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Bilirubin is an asymmetrically substituted tetrapyrrole dicarboxylic acid. The 
introduction of CH2 at C-10 of the bilirubin molecule induces a conformational change by 
rotation of dipyrrinone groups around the central CH2 group. This allows intramolecular 
hydrogen bonding of the propionic acid carbonyl to the amino groups of the dipyrrinone 
lactam and the pyrrole ring (Nogales and LlGHTNER 1995) that explain several properties 
of bilirubin, such as its high lipid/water partition coefficient and its resistance to 
hepatobiliary excretion. Bilirubin requires conjugation with glucuronic acid for biliary 
excretion.
2.3 Bilirubin toxicity
The immaturity of most steps of bilirubin metabolism causes a mild, temporary 
retention of unconjugated bilirubin (UCB) in approximately 60% of healthy term neonates 
who show serum UCB levels of less than 170 pM (10 mg/dL) within the first days of life 
(Ostrow et al 1994). The hyperbilirubinemia is clinically evidenced by deposition of 
bilirubin in the sclera and in the skin that became yellow. The term ‘icterus’ from the Greek 
ikteros or “jaundice” from the French “jaune” that mean yellow, is used to describe this 
condition. The neonatal jaundice resolves spontaneously without sequelae within the first 
week of life in most cases (OSTROW et al 2003). However, moderate hyperbilirubinemia, 
(200-300 pM; 11.7 mg/dL) occurs in at least 16% of infants. The increased uptake of UCB 
into the central nervous system may cause transitory effects such as hypotonia, lethargy, 
anorexia, poor suckling, and development of bilirubin encephalopathy or bilirubin induced 
neuronal dysfunction (BIND) that is usually reversible.
In about 2% of infant with higher or prolonged hyperbilirubinemia (UCB >13-26 
mg/dL; 220-440 pM) there is increased risk of permanent neurological complications
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ranging from motor development delay, impaired cognitive functions, auditory 
dysfunctions to more severe motor, auditory and cognitive disorders, and death (SOORANI- 
Lunsing et al. 2001). Yellow discoloration of the hippocampus, basal ganglia and nuclei of 
cerebellum and brain stem found in infants with acute bilirubin encephalopathy is termed 
kernicterus that means "yellow kern," with kern indicating the most commonly afflicted 
region of the brain (i.e., the nuclear region). At serum unconjugated bilirubin 
concentrations over 20 mg/dL, newborn babies are at risk of kernicterus.
The treatment of neonatal jaundice is based on phototherapy that converts UCB into 
photoisomers that can be excreted in bile and urine. In newborns with severe jaundice, 
more aggressive treatments including exchange transfusion to physically remove UCB from 
the circulation are undertaken.
UCB is toxic to many cell types and it inhibits DNA synthesis (SCHIFF et al. 1985), 
ATPase activity of brain mitochondria (MUSTAFA et al. 1969), and uncouples oxidative 
phosphorylation. Which of these toxic effects is the cause of bilirubin encephalopathy 
remains unclear at this time. Because the toxic effects of bilirubin are abrogated by tight 
binding to albumin, cerebral toxicity is usually observed when there is a molar excess of 
bilirubin over albumin in plasma.
2.4 UCB glucuronidation
Unconjugated bilirubin circulates in plasma only bound tightly but reversibly to 
serum albumin, which prevents its excretion in urine, except during albuminuria. Albumin 
binding keeps bilirubin in solution and abrogates its toxic effects. Conjugated bilirubin is 
bound less tightly to albumin, and the unbound fraction is excreted in the urine.
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At the sinusoidal surface of the hepatocyte (Figure 3), bilirubin dissociates from 
albumin and is taken up by the hepatocyte by facilitated diffusion that requires inorganic 
anions, such as Cl-. The protein(s) involved in sinusoidal bilirubin uptake have not been 
identified yet. A member of the organic anion transport protein family, named OATP2 (also 
termed SLC21A6), has been proposed as the sinusoidal bilirubin transporter (Cui et al 
2001), but its importance in bilirubin transport has been questioned (Wang et al 2003).
Once in the hepatocyte, bilirubin is bound to major cytosolic proteins, glutathione- 
S-transferases (GSTs, formerly designated as ligandin or Y-protein). GST is a small basic 
component making up to 6% of total cytosolic proteins of the liver. Bilirubin is a ligand for 
GSTs, but not a substrate for glutathione transferases. Binding to GSTs reduces the efflux 
of bilirubin from hepatocytes, thereby increasing its net uptake. GST binding inhibits non­
specific diffusion of bilirubin into various subcellular compartments, thereby preventing 
specific organel toxicity, such as inhibition of mitochondrial respiration (Kamisaka et al 
1975).
In the hepatocyte, the propionyl side chains of bilirubin are conjugated to form a 
diglucuronide. The reaction is catalized by UDPGT that utilizes uridine 
diphosphoglucuronate (UDPGA) as a glucuronate donor to bilirubin (Figure 4). The 
conversion of unconjugated bilirubin to bilirubin diglucuronide or monoglucuronide is 
critical for efficient biliary excretion of bilirubin.
In normal bile, the diglucuronide is the major form of excreted bilirubin and only 
small amounts of monoglucuronide or other glycosidic adducts are present. Unconjugated 
bilirubin accounts for less than 10%. In addition to glucuronides, small amount of glucosyl, 
xylosyl and mixed conjugates of bilirubin are found in human bile.
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P la sm a  m e m b r a n e
Tight ju n c t io n
Bile C analicu lus
c y to s o l
ER lu m e n  ▼
Figure 3. Hepatocye bilirubin metabolism. Bilirubin is transported from sites of 
production to hepatic sinusoids bound to albumin. At sinusoidal surface of hepatocytes, 
bilirubin dissociates from albumin and enters hepatocytes by facilitated diffusion. Binding 
to cytosolic GST increases net uptake of bilirubin by inhibiting its efflux. Bilirubin is 
converted to mono- and diglucuronide by the UGT1A1, which catalyses the transfer of the 
glucuronic acid moiety from UDPGA to bilirubin. Bilirubin glucuronides (Bilirubin GA) are 
actively transported into bile against a concentration gradient by the ATP-utilizing pump 
MRP2.
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HOOC COOH
H H
Bilirubin
OH OHHOOC
UDPGA UDP
■OH
•COOHHO' HOUGT1A1
15,
Bilirubin diglucuronide
Figure 4. Bilirubin glucuronidation reaction catalyzed by UGT1A1.
Bilirubin diglucuronide is much more water-soluble than free bilirubin, and thus the 
transferase facilitates excretion of bilirubin into the bile.
Conjugated bilirubin undergoes unidirectional transport into the bile against a 
concentration gradient, so that bilirubin concentration in the bile can be up to 150-fold 
higher than hepatocyte concentration. The electrochemical gradient of -35 mV, generated 
by the sodium pump, helps the canalicular transport but it is not sufficient by itself to 
generate such a large concentration gradient. The energy for transport of bilirubin is derived 
from adenosine triphosphate (ATP) hydrolysis by the canalicular ATP-binding cassette 
protein, the MDR-related protein 2 (MRP2). MRP2 pumps glutathione-, glucuronic acid- or 
sulphate-conjugated compounds across the canalicular membrane (Ishikawa et al. 1990; 
N ishida et al. 1992). Canalicular transport of organic anions is unidirectional from the 
cytoplasm of the hepatocyte to the bile.
2.5 The UGT family
Uridine diphosphoglucuronate glucuronosyl transferases (UGTs) are a superfamily 
of enzymes concentrated in the endoplasmic reticulum (ER) and nuclear envelope of 
several cell types and catalyze glucuronidation of several molecules. These enzymes play 
an important role in clearance of environmental toxins, endogenous metabolites, and drugs. 
They catalyze transfer of glucuronic acid moiety of UDPGA to the aglycone substrates, 
forming polar and usually less bioreactive products. Bilirubin glucuronidation is catalyzed 
predominantly by a single UGT isoform, the UGT1A1 (Bosma et al. 1994).
Based on identity in amino acid sequence, UGTs are divided into two families, 
UGT1 and UGT2 (Burchell et al. 1991). Members o f the UGT1 gene family include
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bilirubin- and phenol-metabolizing isoforms. The UGT1 subfamily of UGT proteins 
catalyzes the glucuronidation of donor substrate (UDPGA) to several acceptor substrates. 
The diversity of UGT1 proteins is determined by the genomic organization of genes 
encoding for them. The rat and human UGT1 clusters have been well characterized (Emi et 
al. 1995). Nine iso forms within the UGT1A subfamily are expressed from a series of exons 
clustered in a unique manner on chromosome 2 at the 2q37 region. Four consecutive exons 
(exons 2-5) located at the 3' end of the UGT1A locus are used by nine different mRNAs 
(Figure 5). These encode the identical carboxy-terminal domains of these UGT isoforms, 
which contain the UDPGA binding site. Upstream of these four common region exons is a 
series of unique exons, each preceded by a separate promoter. Only one of these exons is 
used in a specific UGT mRNA. The unique exon encodes the variable N-terminal domain 
of the nine different UGT isoforms dictate aglycone specificity to each individual iso forms. 
Depending on the promoter used, transcripts of various lengths are generated. In all cases, 
the unique exon, located at the 5' end of the transcript, is spliced to exon 2, and the 
intervening sequence is spliced out. The genes are named according to the unique first 
exon. Thus, UGT1A1 utilizes the unique exon 1A1, UGT1A6 utilizes exon 1A6, etc. The 
presence of a separate promoter upstream from each unique exon permits differential 
regulation of individual UGT isoforms during development and in response to inducing 
agents.
UGT1A1 is expressed after birth and is induced by phenobarbital and clofibrate 
(CHOWDHURY et al 1983). Delayed expression of UGT1A1 is a major cause of neonatal 
hyperbilirubinaemia. In humans, the expression of UGT1A1 is limited to hepatocytes and, 
to a lesser extent, to the proximal small intestine.
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UGT1A1 mRNA
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Figure 5. Organization of the UGT1 gene complex locus. This locus contains at 
least eight exons 1, which can be spliced to common exons 2 through 5. The first exons 
are named 1A1, 1A2, 1A3, etc, and accordingly their gene products are named UGT1A1, 
UGT1A2, UGT1A3, etc.
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The DNA sequence of UGTs contains an amino-terminal signal peptide, which is 
cleaved during synthesis of the polypeptide chain (Iyanagi et al 1986), and a stretch of 17 
hydrophobic amino acids near the carboxy terminus, that anchors the protein to the lipid 
bilayer (Mackenzie 1986). The stretch o f20-30 amino acids at the carboxy terminus of the 
UGT contains several basic residues, which are responsible for retaining the UGT in the ER 
(KlNOSAKI et al 1993).
Members of the UGT2 family include steroid-metabolizing isoforms. Comparison 
of the amino acid sequences of the proteins encoded by the UGT2 gene family reveals 
differences in amino acid sequence throughout the length of the protein. The carboxy- 
terminal halves, however, are highly conserved, which may provide the binding site for the 
common co-substrate, UDPGA (Iyanagi et al 1986; Mackenzie 1986).
2.6 Molecular defect in CN type I syndrome
Mutations in the UGT1A1 gene are responsible for both type I and type II CN and 
were first described in 1992 (BOSMA et al 1992a; Bosma et al 1992b; Bosma et al 1994). 
The genetic lesions can be deletions, insertions, missense mutations, or premature stop 
codons (Kadakol et al 2000). The severity of the functional deficiency of UGT1A1 is 
determined by the nature of the genetic lesion. CN type I results from premature truncation 
or critical amino acid residue substitution whereas CN type II is caused by substitution of 
single amino acid residues that reduce but not abolish the enzyme activity. The TA 
insertion within a dinucleotide repeat in the promoter region of UGT1A1 gene is 
responsible for Gilbert syndrome. The normal TATAA element sequence is A(TA)6TAA, 
whereas in Gilbert syndrome the sequence is A(TA)yTAA. The variant TATAA element 
reduces the expression of the structurally normal enzyme (BOSMA et al 1995).
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2.7 Current Therapies for Crigler-Najjar Syndrome
Treatment of CN is mainly based on inhibition of bilirubin production (heme 
oxygenase inhibitors), stimulation of bilirubin metabolism (phenobarbital), increase 
clearance of bilirubin (phototherapy), and removal of excessive bilirubin by plasma 
exchange transfusion in the severe cases.
The main therapy for CN type I is phototherapy. The visible blue lights (420-460 
nm) transform the bilirubin in its photoisomers (referred also as photobilirubin and 
lumirubin) which are water soluble and therefore can be excreted in the urine. Phototherapy 
has to be carried out for at least 10-12 hours using lamps that emit light with appropriate 
wavelengths. The amount of time required under bilirubin lights tends to increase with age 
as there is a change in ratio of body surface area to body mass (Cremer et al 1958). 
Plasmapheresis is the most efficient method for rapidly reducing serum bilirubin 
concentration during acute crisis. Given the increased risks of irreversible brain damage 
and death, patients with CN type I are often advised to consider liver transplantation, most 
frequently in the range of 18-25 years of age. Orthotopic or auxiliary liver transplantation 
rapidly normalizes serum bilirubin levels. Currently, liver transplantation is considered the 
only definitive treatment for CN type I. However, liver transplantation is far from being an 
ideal therapy because is limited by the number of donor organs available, transplant 
mortality and morbidity, and life-long immunosuppression.
Hepatocyte transplantation (transplantation of hepatic cells, i.e. hepatocytes, rather 
than whole liver) is an alternative to liver transplantation. Matas et al. have demonstrated 
that infusions of immunosuppressed Gunn rats with normal hepatocytes via the portal vein 
result in reduction of plasma bilirubin concentration, ameliorating clinical symptoms of the 
disease (Matas et al. 1976). Two decades later, Fox et al. treated a patient with CN type I
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with hepatocyte transplantation (Fox et al. 1998). The 11-year-old girl with CN was 
transplanted with 7.5 billion isolated allogeneic primary human hepatocytes by infusion 
through a percutaneously placed portal venous catheter (Chowdhury et al 1998; Fox et 
al. 1998). Tacrolimus was used for prevention of allograft rejection. The procedure resulted 
in excretion of bilirubin glucuronides in bile, and an approximately 50% reduction of serum 
bilirubin concentration over the course of several months. Unfortunately, the amount of 
bilirubin-UGT enzyme activity derived from the transplanted cells was not sufficient to 
eliminate the patient need for organ transplantation.
Given the limitations of currently available treatments, it would be desirable to 
develop more effective treatments for this severe disease, and gene therapy has a great 
potential to provide a definitive cure for this disorder (Miranda and BOSMA 2009).
2.8 Animal models of Crigler-Najjar syndrome type I
The Gunn rat is a mutant strain of Wistar rats that lacks the UDPGT activity toward 
bilirubin and develops unconjugated hyperbilirubinemia (Figure 6A). In this animal model 
the genetic lesion closely parallel those in CN type I (CHOWDHURY et al. 1993) and the 
brain lesions are similar to those in humans, with cell loss and gliosis most prominent in the 
auditory nuclei of the brainstem, the cerebellum, the hippocampus and the basal ganglia 
(Chowdhury et al. 1993). This strain carries a spontaneous single-base-pair deletion of the 
UGT1A1 gene. The deletion of a single base pairs in the UGT1 common exon 4 produces a 
stop codon that remove the 115 amino acids from the carboxy terminus of the protein 
(approximately 13 KDa) responsible for the binding on the ER (Figure 6B). The mutant 
protein is unstable and rapidly degraded (BURCHELL et al. 1991; CHOWDHURY et al. 1993;
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elAwady et al 1990; IYANAGI et al. 1989). Pulse-chase experiments using primary cell 
cultures showed that the truncated UGT1 Al protein of Gunn rat is synthesized similarly to 
wild-type protein. However, the truncated UGT1 Al protein is degraded more rapidly with a 
half-life of about 50 minutes, whereas the wild-type UGT1A1 protein has a much longer 
half-life of about 10 hours (Figure 6C, D) (Emi et al. 2002). In Gunn rat the mutation in the 
exon 4 (common) causes the simultaneous deficiencies of all UGT1 isoforms (Emi et al 
1995).
The homozygous j j  Gunn rats have hyperbilirubinemia (CHOWDHURY et al 1991; 
Iyanagi et al. 1989) while the non jaundiced heterozygous Jj rats have normal serum 
bilirubin (SCHMID et al 1958). Total serum bilirubin (TSB) levels in Gunn rats range from 
3 mg/dL (50 pM) to 20 mg/dL (340 pM) depending on the strain and the diet (normal TSB 
levels in rats are 0.01-0.05 mg/dL). The bile of homozygous Gunn rats contains trace 
amounts of bilirubin mono-conjugates (Blanckaert et al 1977; WlSHART 1978).
For more than 60 years, Gunn rats have been intensively used both to understand 
the disease pathogenesis and to develop therapeutic approaches (CHOWDHURY et al 1993). 
The disease in Gunn rats is relatively milder compared to humans affected by CN type I.
The Gunn rats survive and reach adulthood without any treatment, and they may 
only show cerebellar hypoplasia, hearing impairment, and minor behavioral defects 
(Chowdhury et al. 1993) which disappear after a short period of phototherapy. Despite 
these important differences with the human disease, this animal model has been highly 
instrumental to better understand the biology of CN and to validate a wide variety of 
therapeutic approaches.
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Figure 6. The Gunn rat. A. Gunn rats at 3 and 20 days post-natal age. The j j  
hyperbilirubinemic rats (arrows) exhibit yellow discoloration of the skin (see ears and tail) 
and coat, whereas heterozygous (Jj) animals show normal skin and coat color. B. 
Nucleotide sequence of UDPGT cDNAs from normal Wistar and homozygous Gunn rats. 
The deletion is marked with an asterisk. C, D. Absence of UGT1A1 protein in Gunn rat 
hepatocytes (Emi et al., 2002). The UGT1A1 mRNA is present in Gunn rats even if at 
lower amounts but the protein is undetectable. The mutation in Gunn rats results in 
accelerated degradation of truncated UGT1A1 protein.
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Nguyen et al. in 2008 generated a mouse model in which the coding region of exon 
4 has been interrupted resulting in levels of UCB that are comparable to those observed in 
patients. The absence of functional UGT1A protein predisposes neonatal mice to fatal 
consequences related to the high levels of unconjugated hyperbilirubinemia (Fujiwara et 
al. 2010; N guyen et al. 2008). Despite having an identical mutation, the phenotype 
observed in the mice is much more severe than the Gunn rats. The reasons for such striking 
differences are not known. Another mouse model carrying a 1-base deletion in exon 4 of 
the Ugtl has also been generated and it shows a similar phenotype (BORTOLUSSI et al. 
2012). The hyperbilirubinemia in these mice was corrected by intraperitoneal injection of 
an AAV9 vector expressing the hUGTlAl under the control of the ubiquitous CMV 
promoter.
2.9 Gene therapy for Crigler-Najjar syndrome type I
Over the last two decades, ex vivo and in vivo gene therapy using viral and non-viral 
vectors has been used to correct hyperbilirubinemia in the animal models of CN (Bellodi- 
Privato et al. 2005; Kren et al. 1999; Miranda and Bosma 2009; N guyen et al. 2007; 
Sauter et al. 2000; Schmitt et al. 2010b; Seppen et al. 2003; Takahashi et al. 1996; 
Toietta et al. 2005).
An important advantage of ex-vivo gene therapy is that triggering of innate immune 
responses is avoided (Miranda and Bosma 2009). In addition, it prevents systemic 
dissemination of the vector to multiple tissues that are not relevant for disease correction. 
Ex-vivo gene therapy has been used successfully to correct deficiencies in hematopoietic 
stem cells (Qasim et al. 2004). The success of this approach is dependent on efficient
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repopulation of the hematopoietic system by the corrected cells due to their growth 
advantage over uncorrected cells. In hepatic disorders that result in hepatocyte injury, 
efficient repopulation of the liver can also be achieved (De Vree et al 2000; Overturf et 
al 1998). However, in most inherited inborn errors of liver metabolism, including CN, 
corrected hepatocytes do not have a selective growth advantage and thus the efficacy of 
transplanted genetically modified cells is limited.
Correction of CN type I by gene therapy has been the goal of several in vivo studies 
using different vector systems including Retrovirus (RV), Lentivirus (LV), Adenovirus 
(Ad), Adeno-Associated Virus (AAV), and non-viral vectors. RV expressing UGT1A1 
injected in newborns (Bellodi-Privato et al. 2005) or in conjunction with partial 
hepatectomy (Tada et al. 1998) has achieved long-term correction of hyperbilirubinemia in 
the Gunn rats. LV vectors can also transduce non-proliferating cells and in the Gunn rats 
they resulted in stable reduction of bilirubin levels to near normal levels for over 1 year 
after treatment (VAN DER WEGEN et al 2006). Nguyen et al. also reported that delivery of 
murine leukemia virus (MLV)-based retroviral or lentiviral vectors to newborn Gunn rats 
resulted in sustained reduction of hyperbilirubinemia for at least 40 weeks (Bellodi- 
Privato et al 2005; N guyen et al 2005; Schmitt et al 2010a; Schmitt et al 2010b).
Impressive lifelong correction of hyperbilirubinemia has been reported in the Gunn 
rats following a single intravenous injection of helper-dependent adenoviral vector (HDAd) 
encoding UGT1A1 with negligible chronic toxicity (Toietta et al 2005). Recently, it has 
been demonstrated that an improved expression cassette combined with a more efficient 
method of vector delivery (hydrodynamic injection) permits correction of 
hyperbilirubinemia in the Gunn rat using clinically relevant low HD Ad doses (DlMMOCK et 
al 2011). As a part of a research project, not included in this thesis work, I have also
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recently demonstrated that direct intrahepatic injections, by either surgical exposure of the 
liver or by ultrasound-guided percutaneous injections, of HDAd vector expressing 
UGT1A1 results in improved phenotypic correction at low clinically relevant doses 
compared to systemic intravenous injections (Pastore et al, submitted). In addition, a 
reduction of hyperbilirubinemia has also been reported following hydrodynamic injection 
of pDNA (JlA and DANKO 2005b).
Among the different vectors used so far, AAV vectors have emerged as the most 
promising. A previous study has investigated different serotypes in Gunn rats and AAV 1 
was previously found to be the most efficient for correction of the hyperbilirubinemia. It 
has to be noted that in that study a large hepatic macroscopic lipid lesions of unclear 
etiology were found in AAV-treated animals (Seppen et al 2006).
Glucuronidation of bilirubin can occur in tissues other than liver and still result in 
reduction of hyperbilirubinemia. For example Seppen et al. (Seppen et al 1997) used RV 
vectors to transfer the human UGT1A1 gene into autologous ear fibroblasts of the Gunn 
rats that were then injected into the peritoneum. This therapeutic strategy resulted in 
complete correction of serum bilirubin levels. However, the animals developed cancer 
because injected fibroblasts acquired tumorigenic properties due to prolonged culturing in 
vitro. Nevertheless, this study demonstrates that expression of UGT1 Al in an ectopic tissue 
corrects the hyperbilirubinemia in the animal model of CN.
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3. SPECIFIC AIMS
The overall goal of my thesis was to generate preclinical data to support clinical 
applications of a gene-based strategy for the therapy of CN type I patients. Towards this 
goal, I focused on two main approaches one based on muscle gene transfer and another on 
liver-directed gene therapy.
Although correction of the deficient enzymatic activity in the affected organ, i.e. the 
liver, would be the most straightforward, expression within an ectopic tissue, different from 
the natural production site, is an attractive option for clearance of toxic metabolites from 
the circulation. Interestingly, transplantation of small-bowel and kidney, which also express 
UDPGT, were effective at reducing the hyperbilirubinemia in Gunn rats, thus suggesting 
that ectopic expression of the enzyme is sufficient for metabolic correction of the disease 
(KOKUDO et al 1999).
Muscle has been the preferred target tissue for gene transfer because of its simple 
access by intramuscular injections and safety. AAV vectors are ideal candidates for muscle- 
directed gene therapy approaches and they have shown encouraging results in various 
preclinical disease models. Moreover, those studies have led to multiple human clinical 
trials (Brantly et al 2009; Manno et al. 2003; Stroes et al 2008) and to the 
development of Glybera (alipogene tiparvovec), an AAV vector for muscle gene therapy of 
lipoprotein lipase deficiency that has been the first gene-therapy medicine recommended 
for authorization in the European Union (Gaudet et al 2013; Yla-Herttuala 2012).
Previous studies have shown reduction of hyperbilirubinemia in the Gunn rat by 
plasmid DNA delivery into skeletal muscle via limb perfusion (Danko et al 2004; JiA and 
Danko 2005a). In those studies, injections ofpDNA expressing human UGT1A1 under the
37
CMV promoter resulted in excretion of bilirubin glucuronides in bile and short term 
reduction of serum bilirubin lasting for 2 to 4 weeks. Loss of correction was associated with 
a decrease in UDPGT protein in muscle, while pDNA and transcript were detectable up to 4 
weeks after gene delivery. Longer correction required repeated pDNA delivery achieved by 
a relatively invasive procedure and immunosuppression (Danko et al. 2004; JlA and 
Danko 2005a).
The specific aim 1 of my thesis was to investigate the safety and efficacy of 
muscle-directed gene therapy of CN type I using AAV vectors.
Although attractive for its safety, AAV mediated muscle-directed gene therapy of 
CN type I did not result in complete correction of the hyperbilirubinemia in the Gunn rats. 
Encouraged by the promising results of the hemophilia B clinical trial (Nathwani et al 
2011b), I next investigated systemic intravenous injections for liver-directed gene therapy 
of CN type I by AAV vectors. This approach has the potential to completely correct the 
hyperbilirubinemia in CN type I.
Liver-directed gene therapy with AAV vectors has been difficult to accomplish. In 
the first hemophilia B gene therapy trial, the administration of AAV2 encoding the human 
Factor IX (FIX) resulted in transaminase elevation and a decline of FIX levels due to a 
specific immune-mediated destruction of the transduced cells (Manno et al. 2006). The 
mechanisms involved in this immune reaction are not completely understood but it is clear 
that CD8+ T-cells against AAV capsid proteins are involved in the clearance of the 
transduced hepatocytes (Hasbrouck and High 2008). Based on the discovery that other 
AAV serotypes displayed higher tropism for liver compared to AAV2, another clinical trial 
for liver-directed gene therapy was started in hemophilia B patients using serotype 8 AAV 
vector injected through a peripheral vein. In this trial no immune reaction was observed at
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the lower doses while two participants who received the higher dose of vector developed a 
transient, asymptomatic elevation of serum aminotransferase levels which was associated 
with the detection of AAV8-capsid-specific T cells in peripheral blood. Both these 
participants received a short course of glucocorticoid therapy which rapidly normalized 
aminotransferase levels and maintained FIX in the therapeutic range. In all patients, AAV8 
administration resulted in therapeutic FIX levels at 2-11% of normal levels, four of the six 
discontinued FIX prophylaxis and remained free of spontaneous hemorrhage, and in the 
other two the interval between prophylactic clotting factor infusions was increased 
(NATHWANI et al 201 lb).
The specific aim 2 of my thesis work was to optimize the gene therapy vector for 
CN type I and to generate preclinical data using AAV2/8 in the Gunn rats to support a gene 
therapy clinical trial.
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4. MATERIALS AND METHODS
4.1 Construction and production of AAV vectors
The rat UGT1A1 (rUGTlAl) coding sequence was obtained from Wistar rat liver 
mRNA and cloned into the pAAV2.1-MCK-eGFP plasmid (Tessitore et al. 2008) by 
replacement of the enhanced green fluorescent protein (eGFP) sequence (Figure 7A). The 
cloned rUGTl Al sequence was entirely verified by direct DNA sequencing.
The human UGT1A1 (hUGTlAl) coding sequence was cloned downstream the 
thyroxine binding globulin (TBG) promoter into the pAAV2.1-TBG-eGFP plasmid by 
replacing the eGFP sequence (Figure 7B). The pAAV2.1-TBG-hUGTlAl contains the 
simian virus 40 (SV40) intron between the promoter and the cDNA and it also includes the 
Woodchuck Hepatitis Post-Transcriptional Regulatory Element (WPRE) that stabilizes the 
mRNA levels. The hUGTlAl coding sequence was optimized (cohUGTlAl) for the 
expression in Homo sapiens (GeneArt). The codon usage was adapted to the codon bias of 
Homo sapiens genes. In addition, regions of very high (> 80 %) or very low (<30 %) GC 
content have been avoided where possible. During the optimization process the following 
cis-acting sequence motifs were avoided where applicable: -internal TATA-boxes and 
ribosomal entry sites; AT-rich or GC-rich sequence stretches; RNA instability motifs; 
repeat sequences and RNA secondary structures; (cryptic) splice donor and acceptor sites in 
higher eukaryotes. Codon optimized UGT1A1 was cloned into pAAV2.1-TBG-eGFP 
plasmid by replacing the eGFP sequence (Figure 7B).
A fragment containing the LP1 enhancer/promoter [a liver specific promoter 
containing the human apolipoprotein hepatic control region (HCR) and the human alpha-1- 
antitrypsin (hAAT) gene promoter including the 5' untranslated region] and the SV40
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Figure 7. A. Muscle-specific AAV vectors. MCK, muscle specific creatin kinase 
promoter; eGFP, enhanced green fluorescent protein; rllGT1A1, rat uridine diphospho- 
glucuronosyl transferase 1A1 cDNA; WPRE, woodchuck hepatitis post-transcriptional 
regulatory element; BGHpA, bovine growth hormone poly-adenylation signal; ITR, inverted 
terminal repeats. B. Liver-specific AAV vector genomes. TBG, thyroxine binding 
globulin promoter; LP1, liver specific enhancer promoter; SV40 intron, simian virus 40 
intron; hUGT1A1, human uridine diphospho-glucuronosyl transferase 1A1 cDNA; 
cohUGT1A1, codon optimized hUGT1A1; SV40 pA, simian virus 40 late polyadenylation 
signal, ITR, inverted terminal repeats. Not drawn to scale.
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poly-A sequence was amplified using the scAAV-LPl-hFIX plasmid as template (kindly 
provided by Dr. Nathwani) after elimination of FIX cDNA and SV40 intron and cloned into 
the pAAV2.1-TBG-eGFP plasmid by replacing the TBG-eGFP-WPRE-BGH poly-A 
sequence to generate the pAAV2.1-LPl-SV40pA plasmid. The hUGTlAl and the 
cohUGTlAl coding regions were cloned into the pAAV2.1-LPl-SV40pA plasmid (Figure 
7B).
The AAV vectors were produced and characterized by the Telethon Institute of 
Genetics and Medicine Vector Core (Naples, Italy). The pAAV2.1-MCK-rUGTlAl, 
pAAV2.1-MCK-EGFP, pAAV2.1-TBG-hUGTlAl, pAAV2.1-LPl-hUGTlAl, and 
pAAV2.1-LPl-cohUGTlAl plasmids were triple-transfected in subconfluent 293 cells 
along with pAd-Helper and pack2/l packaging plasmids as described previously (XlAO et 
al. 1999). Recombinant vectors were purified by two rounds of CsCl gradient 
centrifugation, as described previously (XlAO et al 1999). Vector titers, expressed as 
genome copies per milliliter (GC/ml), were measured by both PCR quantification 
(TaqMan; PerkinElmer, Life and Analytical Sciences, Waltham, MA) and dot-blot analysis. 
For the comparison of AAV vectors with different expression cassettes for liver-directed 
gene therapy, the vector titer was calculated using serial dilutions of the plasmid AAV- 
TBG-hUGTlAl and AAV specific primers (ITR F: 5 ’-GGAACCCCTAGTGATGGAGTT- 
3’ and ITR R: 5’-CGGCCTCAGTGAGCGA-3’); the results were analyzed with 
LightCycler software version 3.5 (Roche).
4.2 Animal experiments
Animal procedures were performed in accordance with the regulations of the Italian 
Ministry of Health. Breeding pairs of Gunn rats were obtained from the Rat Resource and
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Research Center (RRRC, Columbia, MO) and a colony of Gunn rats was established at the 
Institute of Genetics and Biophysics-Telethon Institute of Genetics and Medicine (IGB- 
TIGEM) animal facility (Naples, Italy).
For intramuscular (IM) injections, three injections (each of 30 pi each) were 
performed in the gastrocnemius of 4-to-6 week-old male Gunn rats (75-150 g), for a total 
vector dose of 3xl012 genome copies (GC)/kg of AAV2/l-MCK-eGFP (n = 3), AAV2/1- 
MCK-rUGTlAl (n = 9), or saline (n = 5), using a 100-pl Hamilton syringe. Following 
vector injections, blood samples were collected by retro-orbital venipuncture at 3 weeks 
post-injection and each month thereafter. Bile was collected through a 26-gauge 
angiocatheter (Delta Med, Milan, Italy) inserted into the bile duct over 15-minute periods, 
protected from light, frozen, and store at -80°C until analyses. Random urine spots were 
collected for measurement of alkali-labile bilirubin concentrations. Urinary creatinine was 
measured by colorimetric assay based on the Jaffe method (Clarke 1961). Creatine 
phosphokinase (CPK) was measured in serum samples in the first week and 3, 15, 24, and 
52 weeks post-injection (Gentaur, Milan, Italy). To determine UGT1A1 activity, muscle 
and liver tissues were collected at 4 and 12 months post-injection. Tissues for real-time 
PCR were harvested from Gunn rats injected intramuscularly at 1,4, and 12 months after 
injection.
For intravenous (IV) injections, AAV vectors or saline were injected in the tail vein 
of 4-to-6 week-old female Gunn rats (65-130 g) using a 26G needle. Following injections, 
blood samples were collected by retro-orbital venipuncture at 2 weeks post-injection and 
each month thereafter. Tissues for real-time PCR and western blot were harvested at 3 
months post-injection.
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4.3 Bilirubin determinations
Blood was centrifuged at 4000xg for 20 minutes and 8000xg for 10 minutes. Serum 
was used for colorimetric measurement of total bilirubin by a diazo-based assay (Gentaur, 
Belgium). The average serum bilirubin measured in 40 wild-type 3-4 week old Wistar rats 
was 0.91 - 0.51 mg/dl.
Biliary, serum, and urinary unconjugated bilirubin and alkali-labile pigment 
concentrations were determined by high-performance liquid chromatography (HPLC) as 
previously described (Zelenka et al 2008). Unconjugated bilirubin was measured before 
and after the addition of 1M NaOH to the sample for 10 minutes, and the concentration of 
alkali-labile bilirubin pigments, expressed as bilirubin equivalents, was calculated from the 
difference between the two measurements. Qualitative analysis of bilirubin pigments in bile 
was performed by direct HPLC of undiluted bile by the McDonagh method (Toietta et al 
2005) by our collaborator Dr. Antony McDonagh from University of California San 
Francisco (UCSF). Bilirubin determination in bile was performed by the collaborators Jana 
Vanikova and Libor Vitek, from Institute of Clinical Biochemistry and Laboratory 
Medicine, Charles University in Prague (Czech Republic).
4.4 Western blot analysis, enzyme assay, and qPCR on tissues
Muscle and liver samples were homogenized in 0.5 ml of phosphate-buffered saline 
(pH 7.4), using a TissueLyser homogenizer (Qiagen, Milan, Italy). The tissue homogenate 
was mixed with 4 ml of microsome buffer (2.62 mM KH2PO4 , 1.38 mM K2HPO4 , 2% 
glycerol, and 0.5 mM dithiothreitol) and first centrifuged at 12,000xg for 20 minutes at 
4°C. The supernatant was then re-centrifuged at 105,000xg for 60 minutes at 4°C. The 
pellet was resuspended in microsome buffer and the protein concentration was determined
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by the Bradford method. Microsomal extracts were characterized by detection of a calnexin 
band by Western blotting using anti-calnexin antibody (Assay Designs, Ann Arbor, 
MI).These extracts were used to measure UGT1A1 activity. Approximately 10-20 pg of 
microsomal proteins from Wistar and Gunn rat livers and muscles were separated by 
sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and blotted onto 
PVDF membrane. Goat anti-rat UGT1A1 antiserum (diluted 1:1000; Santa Cruz 
Biotechnology, Santa Cruz, CA) with rabbit anti-goat IgG (diluted 1:3000; BioVision, 
Mountain View, CA) were used for immunodetection. Membranes were developed with an 
enhanced chemiluminescence kit (Thermo Scientific, Milan, Italy) and detected with 
Chemi- Doc (Bio-Rad, Hercules, CA).
UGT1A1 enzyme activity in muscle microsomes was measured according to a 
previously published assay using bilirubin as substrate (Heirwegh et al. 1972).
Total DNA was extracted from tissue samples using pheno 1-chloroform extraction 
and quantitated by absorbance at 260 nm.
Total RNA was extracted from livers of IV injected animals immediately placed in 
TRIzol reagent (Invitrogen, Monza, Italy) using an RNeasy kit (Qiagen, Italy). RNA was 
reverse transcribed using a first-strand complementary deoxyribonucleic acid kit with 
random primers according to the manufacturer’s protocol (Applied Biosystems, Monza, 
Italy).
Quantitative real-time PCR for genome copies was performed with LightCycler 
FastStart DNA master SYBR green I (Roche, Indianapolis, IN) in a total volume of 20 pi 
with 100 ng of template DNA and a 1 pM concentration each of AAV-specific primers 
(BGH F: 5’-TCTAGTTGCCAGCCATCTGTTGT-3’ and BGH R: 5’-
TGGGAGTGGC ACCTTCC A-3 ’ for IM injected Gunn; ITR F: 5’-
45
GGAACCCCTAGTGATGGAGTT-3’ and ITR R: 5’- GGAACCCCTAGTGATGGAGTT- 
3’ for IV injected Gunn). Cycling conditions consisted of 95°C for 10 minutes followed by 
45 cycles at 95°C for 10 seconds, 60°C for 7 seconds, and 72°C for 20 seconds. Serial 
dilutions of a plasmid bearing the PCR target sequence were used as a control to determine 
the amounts of AAV and results were analyzed with LightCycler software version 3.5 
(Roche).
Copies of hUGTlAl mRNA in liver samples of IV injected animals were calculated 
by qPCR using primers that recognize either the wild-type or the codon optimized form of 
the hUGTlAl (hUGT/co F: 5’-CTGCTGCTGTGTGTGCTGGGC-3’ and hUGT/co R: 5’- 
CTGCTGCAGCTGCTGGATGGC-3’). Cycling conditions were 95°C for 10 minutes 
followed by 45 cycles at 95°C for 10 seconds, 70°C for 7 seconds, and 72°C for 20 
seconds.
4.5 GFP expression in muscle
Following, IM injections, the following tissues were harvested from the Gunn rats: 
muscles (gastrocnemius, tibialis), liver, kidney, spleen, and heart. Tissues were fixed in 4% 
paraformaldehyde (PFA) for 24 hours. Muscle and liver specimens were embedded into 
paraffin blocks and sectioned into 10-pm serial sections, using a microtome, and GFP 
fluorescence was visualized with a Zeiss microscope. Total RNA was extracted from liver, 
muscle, spleen, kidney, and heart in TRIzol reagent (Invitrogen, Monza, Italy) using an 
RNeasy kit (Qiagen, Italy). RNA was reverse transcribed as described above.
Primers for amplification of a 95-bp fragment of GFP were as the following: GFP F, 
5 ’-ACGACGGCAACTACAAGACC-3 ’; and GFP R, 5 ’-GTCCTCCTTGAAGTCGATGC- 
3’. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as loading control. A
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136-bp segment of GAPDH was amplified with the following primers: GAPDH F 5’-ATG 
ACTCTACCCACGGCAAG-3’ and GAPDH R 5’-TAC TCAGCACCAGCATCACC-3’. 
Reaction conditions were as follows: reverse transcribed products were subjected to 39 
cycles of amplification with 2.5U of Taq DNA polymerase in 50 pi. After an initial 
denaturing cycle at 95°C for 7 minutes, subsequent cycles consisted of denaturation for 1 
minute at 95°C; annealing for 1 minute at 60°C; and extension for 1 minute at 72°C.
4.6 Statistical analysis
Data are expressed as mean values ± standard deviations in the bar and line plots. 
Statistical significance was computed using the Student’s 2 tail test. A p-value <0.05 was 
considered statistically significant.
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5 . RESULTS
5.1 Sustained reduction of hyperbilirubinemia and excretion of conjugated bilirubin 
in bile and urine following muscle-directed AAV mediated gene transfer in the Gunn 
rats
To investigate muscle-directed AAV mediated gene therapy for CN type I, I 
injected Gunn rats IM with the AAV2/l-MCK-rUGTlAl vector, encoding the UGT1A1
1 9under the control of a muscle-specific promoter at the dose of 3x10 GC/kg. The vector 
dose was chosen on the basis of previous studies applying a similar dose in animal models 
and humans (Arruda et al 2004; Manno et al 2003). Blood samples were collected at 
baseline, 3 weeks after IM injections, and monthly thereafter for measurements of total 
serum bilirubin levels. As expected, baseline levels of total serum bilirubin in Gunn rats 
injected with AAV vector or saline were higher (7.95 ± 1.8mg/dl) than the wild-type Wistar 
rat levels (0.91 ± 0.51mg/dl). In Gunn rats injected with AAV vector, I observed an average 
51% reduction of serum bilirubin compared to saline controls. This reduction was sustained 
for at least 51 weeks (Figure 8). Reduction in total serum bilirubin levels was not observed 
in saline-injected rats (Figure 8). The difference in serum bilirubin in AAV injected rats 
was statistically significant (p < 0.05) compared to saline control group throughout the 
period of study (Figure 8).
To monitor muscle damage after IM injections, serum CPK levels were measured at 
various time points (24 and 48 hours, and 1, 3, 15, 24, and 52 weeks post-injection) after 
IM injections and found to be not higher than saline-injected animals (Figure 9).
To determine whether the reduction in serum bilirubin in vector-injected animals 
was due to enhanced biliary excretion of bilirubin metabolites, bile was collected by 
cannulation of the common bile duct from AAV- and saline-injected animals at 51 weeks
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Figure 8. AAV-mediated muscle-directed gene transfer of UGT1A1 results in 
sustained reduction of hyperbilirubinemia in Gunn rats. Serum bilirubin levels in Gunn 
rats were measured at baseline and after IM injection of AAV2/1-MCK-rUGT1A1 (n = 9) or 
saline (n = 5). Following AAV vector IM injection, reduction of serum bilirubin was 
sustained for at least 51 weeks. This reduction was on average approximately 51% 
compared to saline injected controls (*p<0.05; **p<0.01).
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Figure 9. Evaluation of muscle damage following IM injections. Serum CPK 
levels were determined at various time points (24 and 48 hours, 1-3-15-24-52 weeks) post­
vector administration.
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post-injection. Analysis of bile (Zelenka et al. 2008) showed an increase in alkali-labile 
bilirubin pigments in bile of AAV-injected animals compared to saline-injected controls 
(p< 0.05) (Figure 10A).
Similar analysis showed that AAV-injected animals also had increased excretion of 
bilirubin pigments in urine compared to saline-injected controls (p < 0.05) (Figure 10B) 
and a reduction in serum unconjugated bilirubin (p<0.05) (Figure 10C). HPLC of bile 
samples showed only trace amounts, if any, of bilirubin glucuronides, but it revealed the 
presence of a polar metabolite peak eluting close to bilirubin diglucuronide (Figure 11). 
Although different, the absorbance of this metabolite was similar to bilirubin diglucuronide 
(Figure 11).
5.2 Expression of functionally active UGT1A1 protein in Gunn rat muscles
A subgroup of Gunn rats injected with either saline (n = 3) or AAV (n = 4) was 
sacrificed at 4 months post-injection to harvest muscle microsomes for determination of 
enzyme activity and UGT1A1 Western blotting. As controls, microsomes were prepared 
from muscle and liver of wild-type Wistar rats. Western blot using an anti-rUGTlAl 
antibody showed a band of 55 kDa, corresponding to rUGTlAl, as shown by the band 
present in normal rat liver microsomes, in AAV-injected muscle microsomes but not in 
muscle microsomes from saline-injected controls (Figure 12). The presence of a band 
corresponding to calnexin confirmed that the purified muscle fractions corresponded to 
microsomes (Figure 12).
In the same extracts used for Western blotting, UGT1A1 activity was measured and 
found to be increased in AAV-injected Gunn rat muscle microsomes relative to saline 
injected muscles (p< 0.05), whereas no UGT1A1 activity was detected in liver of the same
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Figure 10. Bilirubin pigments in bile and urine samples. The amount of alkali- 
labile bilirubin pigments in the (A) bile and (B) urine of AAV-treated Gunn rats or wild-type 
rats, collected 1 year post-injection, was higher than in saline-injected controls (*p < 0.05). 
In bile, alkali-labile bilirubin pigments are expressed as a percentage of total bilirubin. In 
urine the excretion of these pigments was normalized for creatinine concentration. (C) 
Unconjugated bilirubin levels in serum were also found to be reduced (*p < 0.05). CB, 
conjugated bilirubin; UCB, unconjugated bilirubin; WT, wild-type.
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Figure 11. Bile HPLC. HPLC chromatograms of bile from wild-type rats, AAV- 
treated Gunn rats, and saline-injected control Gunn rats. Bile from (A) a wild-type rat 
showed strong bilirubin diglucuronide (BDG) and bilirubin monoglucuronide (BMG) peaks 
along with relatively minor amounts of other, unidentified peaks. Bile from (B) an AAV- 
treated Gunn rat showed a bilirubin metabolite peak, with only traces, if any, of bilirubin 
glucuronides along with unconjugated bilirubin (UCB). The metabolite peak was also 
evident in bile HPLC chromatogram from a different AAV treated rat and collected 4 
months post-injection (shown in the inset). (C) Bile from a saline-injected control showed 
an unconjugated bilirubin peak with only a trace of other yellow pigments.
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Figure 12 . UGT1A1 expression in Gunn rat muscle. Western blot analysis for 
rUGT1A1 protein (55 kDa) Gunn rat muscles harvested at 4 and 12 months after the IM 
injections of saline or with AAV2/1-MCK-rUGT1A1. As a control, a liver sample from a 
wild-type rat was used. Microsomal extracts were confirmed by detection of calnexin (89- 
kDa band).
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animals (Figure 13A). Taken together, these results indicate that AAV-transduced muscles 
can express long-term functional UGT1A1 protein.
5.3 Vector biodistribution in intramuscularly injected Gunn rats
Bio distribution of AAV2/l-MCK-rUGTlAl vector by real time PCR showed 
detectable vector genomes only in muscle, whereas the amounts of vector genomes 
detected in other organs (liver, kidney, spleen, and heart) were below the limit of detection 
(<1x10 copies of vector genome) (Figure 13B).
To determine tissue specificity of transgene expression after IM injections and to 
rule out hepatic expression from the MCK promoter, I injected Gunn rats (n = 3) with 
AAV-MCK-GFP at the dose of 3x1012 GC/kg, an AAV vector expressing the reported GFP 
protein under the control of the MCK promoter, and sacrificed the animals at 1 month post­
injection to determine tissue GFP expression and vector genome biodistribution. Injected 
muscles showed extensive GFP staining (Figure 14A, a-b), whereas no staining was 
detected in liver (Figure 14A, c). Expression of the GFP transgene driven by the MCK 
promoter was detected by RT-PCR in muscle, but not in liver or other tissues of the 
injected animals (Figure 14B). Together with the absence of detectable hepatic UGT1A1 
protein by Western blot analysis, these data confirmed that IM injections of AAV2/1- 
MCK-rUGTlAl resulted in muscle-specific expression.
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Figure 13. UGT1A1 expression in Gunn rat muscle e vector biodistribution.
(A) UGT1A1 activity (nmoles of bilirubin per milligram protein per 30 minutes) in muscle 
microsomes from wild-type Wistar rats (n = 3) and in muscles of Gunn rats injected with 
saline (n = 3) or AAV2/1-MCK-rUGT1A1, harvested at 4 and 12 months post-injection (n = 
3 per group). The increase in enzyme activity in AAV-injected muscles was statistically 
significant compared to saline-injected or wild type muscle (*p< 0.05). (B) Analysis of AAV 
vector genome copies showed distribution in muscles and not in other organs (n = 3).
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Figure 14. AAV vector muscle-specific transduction. (A) GFP positive cells 
were detected only in Gunn rat muscle (a-b) and not in liver (c) after IM injection of 3x1012 
GC/kg of AAV2/1-MCK-GFP (n = 3). Nuclei were stained with DAPI. (B) RT-PCR showed 
GFP expression (95-bp fragment) in muscle but not in liver of injected animals. The 136 bp 
corresponding to glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as 
housekeeping control. M1, gastrocnemius; M2, tibialis; L, liver; S, spleen; K, kidney; H, 
heart; CN, negative control.
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5.4 Evaluation of potency of liver specific expression cassettes in vivo
In the perspective of future human applications, it is important to develop a vector 
that has the best chances to result in clinical benefit. Therefore, I decided to investigate the 
potency of various expression cassettes and to determine whether a more potent expression 
cassette results in improved phenotypic correction in CN type I. Although not proven yet, 
being CN type I a non-cell autonomous disorder, it is expected that a vector expressing 
higher levels of UGT1A1 would result in greater reduction of hyperbilirubinemia in Gunn 
rats. Such a vector may allow the use of lower vector dose that will be safer and will reduce 
the risk of the AAV-mediated CTL response that appears to be dose-dependent (N a th w a n i  
et al. 2011a). Therefore, I compared two expression cassettes including either the TBG or 
the LP1 promoter driving hUGTlAl expression. These expression cassettes were then 
inserted within the AAV2/8 vectors that were evaluated for their efficiency in correction of 
hyperbilirubinemia in the Gunn rats. I decided to use the serotype 8 AAV because this 
vector serotype has the greatest hepatotropism in nonhuman primates and has been used 
successfully in hemophilia B patients (N a th w a n i et al 201 lb).I evaluated the efficacy of 
AAV vectors bearing the different expression cassettes at reducing the hyperbilirubinemia 
in vivo. For these studies, I first injected 4-6 week-old female Gunn rats via tail vein with 
saline or with the AAV2/8-TBG-hUGT vector at the dose of 2.7x1013 GC/Kg. Following 
injections, blood samples were collected at 2 weeks and then monthly for determinations of
serum bilirubin. The AAV2/8-TBG-hUGT at this high dose did not result in a significant
1 ^reduction of serum bilirubin levels. Therefore, I next injected the higher dose of 7.4x10 
GC/Kg, that instead, resulted in 30% (5.2 mg/dl) reduction of baseline serum bilirubin by 2 
weeks post-injection and 60% (2.5 mg/dl) reduction by the end of the study at 3-months 
post-injection (Figure 15). Next, I injected Gunn rats with the AAV2/8-LPl-hUGTlAl
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Figure 15. Serum bilirubin levels in Gunn rats after intravenous injections of 
AAV2/8-TBG-hUGT1A1. The vector shown in (A) presents the TBG promoter driving the 
expression of the UGT1A1 transgene (not drawn to scale). Following intravenous 
injections in Gunn rats (B), the AAV2/8-TBG-hUGT1A1 resulted in a significant reduction 
of hyperbilirubinemia only at the dose of 7.4x1013 GC/Kg (**p<0.01).
59
vector at the dose of 2.7xl013 GC/Kg that resulted in 54% (2.2 mg/dl) reduction of baseline 
serum bilirubin by 2 weeks post-injection and this reduction was sustained for the duration 
of the study (Figure 16). Therefore, a three-fold lower dose of the AAV2/8-LPl-hUGTl Al 
vector resulted in a greater reduction of bilirubin levels compared to the AAV2/8-TBG- 
hUGTlAl vector. In contrast, the lower dose of 1.1x1013 GC/Kg did not result in 
reduction of serum bilirubin (Figure 16).
To further enhance UGT1A1 protein expression, I generated an AAV2/8 vector 
including the codon optimized hUGTlAl cDNA under the control of LP1 promoter 
(AAV2/8-LPl-cohUGTlAl). This vector was injected into tail veins of 4-6 week-old 
female Gunn rats at the doses of l.lxlO13 GC/Kg and l.lxlO12 GC/Kg. The AAV2/8-LP1- 
cohUGTlAl resulted in complete normalization of serum bilirubin levels corresponding to 
a 75% (0.76 mg/dl) reduction by 2 weeks post-injection and such correction was sustained 
for the entire period of observation (Figure 17). With a 10-fold lower dose (l.lxlO 12 
GC/Kg), the reduction of serum bilirubin was 30% by 2 weeks post-injection (Figure 17).
Livers from injected rats were collected at the end of the study for DNA and RNA 
extraction to evaluate vector genome copies and hUGTlAl expression. On total RNA 
extracted from livers, using specific primers that recognize the wild-type and the codon 
optimized hUGTlAl, I measured hUGTlAl mRNA levels that were normalized for the 
number of vector genome copies given the different vector doses that were used and to take 
into account possible variability of vector infectivity and injection efficiency (Figure 18B).
I found a significant increase in UGT1A1 expression in AAV2/8-LPl-hUGTlAl injected 
rats compared to AAV2/8-TBG-hUGTlAl injected rats (Figure 18A). A further increase 
in hUGTlAl expression was found in AAV2/8-LPl-cohUGTlAl injected rats. These
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Figure 16. Serum bilirubin levels after intravenous injection of AAV2/8-LP1- 
hUGT1A1. The vector shown in (A) presents the LP1 promoter driving the expression of 
the UGT1A1 transgene (not drawn to scale). (B) The intravenous injection of AAV2/8-LP1- 
hUGT1A1 at the dose of 2.7x1013 GC/Kg resulted in 54% reduction of baseline levels by 2 
weeks post-injection, whereas the injection of the same vector at the dose of 1.1x1013 
GC/Kg did not result in significant reduction of baseline serum bilirubin levels (*p<0.05;
**p<0.01).
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Figure 17. Serum bilirubin levels in Gunn rats injected with AAV2/8-LP1- 
cohUGT1A1. The vector shown in (A) presents the LP1 promoter driving the expression of 
the codon optimized UGT1A1 transgene (not drawn to scale). (B) Intravenous injection of 
AAV2/8-LP1-cohUGT1A1 at the dose of 1.1x1013 GC/Kg resulted in complete 
normalization of serum bilirubin levels by 2 weeks post-injection. The injection of the same 
vector at the further lower dose of 1.1x1012 GC/Kg resulted in 30% reduction of baseline 
serum bilirubin levels (**p<0.01).
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Figure 18. Expression of hUGT1A1 in liver of AAV injected Gunn rats. (A) The
hUGT1A1 mRNA copies were measured in livers of Gunn rats injected with AAV2/8-TBG- 
hUGT1A1 (7.4x1013 GC/Kg), AAV2/8-LP1-hUGT1A1 (2.7x1013 GC/Kg), or AAV2/8-LP1- 
cohUGT1A1 (1.1x1013 GC/Kg). The hUGT1A1 mRNA levels were normalized for the 
amount of AAV vector genome (B) to determine the expression performance of the three 
injected vectors. The bars represent averages ± SD (*p<0.05; **p<0.01).
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results indicate that codon optimization increases expression of hUGTl Al in transduced 
liver cells and are consistent with the concept that beside the effect on translation, codon 
optimization affects gene expression also at the transcriptional and post-transcriptional 
levels by improving mRNA steady-state levels and prolonging mRNA half-lives (F a th  et 
al 2011).
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6. DISCUSSION AND CONCLUSIONS
6.1 Muscle-directed gene therapy for Crigler-Najjar syndrome type I
Patients with Crigler-Najjar syndrome type I have life-threatening elevations of 
serum bilirubin and are currently managed with phototherapy throughout childhood and 
adolescence. Although effective, phototherapy is cumbersome and inconvenient, and its 
efficacy may diminish with age because of increased skin thickness and decreased surface- 
to-mass ratio ( S t r a u s s  et al 2006). Moreover, despite treatment, patients remain at risk of 
brain damage when intercurrent infections may increase production of bilirubin above that 
which can be controlled by phototherapy ( S t r a u s s  et al 2006). Therefore, patients with 
CN type I are often advised to consider liver transplantation, most frequently in the range of 
18-25 years of age.
Muscle-directed gene therapy is attractive for CN type I because skeletal muscle is 
easily and safely accessible by IM injections and contains both dividing and non-dividing 
cells with long half-lives resulting in stable episome expression (JiANG et al 2006; KOO et 
al 2011). For this strategy to be effective in treating hyperbilirubinemia in CN, the enzyme 
produced in the ectopic site must be functional and expressed long term. In this thesis work,
I have shown that expression of the UGT1A1 enzyme in muscle (Figure 12) results in 
long-term reduction of hyperbilirubinemia (Figure 8) without toxicity as demonstrated by 
serial CPK measurement (Figure 9). This finding is supported by the Western blot (Figure 
12) and in vitro UGT1A1 enzyme assay (Figure 13), showing that muscle expresses long 
term a functionally active UGT1A1 protein. Bile and urine of AAV-injected animals 
showed increased excretion of alkali-labile bilirubin derivatives (Figure 10), thus 
suggesting that bilirubin esterified by AAV-transduced muscle cells is excreted in bile and 
urine. However, bilirubin mono- or diglucuronides were not detectable in bile by HPLC
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and only an unidentified metabolite was detected (Figure 10 and 11B). This metabolite is 
reminiscent of the metabolite observed by Seppen and colleagues, who showed correction 
of hyperbilirubinemia in Gunn rats receiving transplantation of cells that do not normally 
express UGT1 Al but were genetically modified ex vivo to express UGT1A1 (Seppen  et al 
1997). It is possible that UGT1A1 expressed in muscle may result in a protein that is not 
identical to the physiological liver-expressed protein, as previously found in the case of 
erythropoietin expressed at ectopic sites (L a sn e  et al 2004; M e n z e l  et al 2009). Whether 
post-translational modifications of muscle-expressed UGT1A1 play a role in the formation 
of this unidentified metabolite is unclear at this time.
The negligible formation of bilirubin glucuronides in the present work despite the in 
vitro detection of UGT1A1 activity in muscle microsomes may reflect inadequate 
formation of the necessary uridine 5 ’-diphosphoglucuronic acid (UDPGA) cofactor (WONG 
1977). Co-expression of UDP glucose dehydrogenase (UGDH), which generates UDPGA, 
may further increase the therapeutic efficacy of muscle-directed gene therapy, as in the case 
of muscle-directed gene therapy of phenylketonuria, which requires the expression of the 
complete phenylalanine hydroxylase (PAH) system (PAH and BH4-biosynthetic enzymes) 
to effectively clear phenylalanine from the blood (D in g  et al 2008). Nevertheless, UGDH 
catalyzes the conversion of UDP-glucose to UDP-glucuronic acid that is used for 
production of proteoglycans, which are involved in promoting normal cellular growth and 
migration (A u v in en  et al 2000; WANG et al 2010). Therefore, overexpression of UGDH 
raises concern for risks of malignant transformation.
Consistent with these results, Bortolussi and colleagues have shown reduction of 
hyperbilirubinemia due to UGT1A1 muscle expression in U gtlal'7' mice injected 
intraperitoneally with an AAV2/9 vector expressing human UGT1A1 under the control of
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the ubiquitous CMV promoter (BORTOLUSSI et al 2012). However, in those studies 
bilirubin glucuronide formation was demonstrated in vitro in muscle microsomes incubated 
with bilirubin and a large excess of UDPGA.
After vector intramuscular injection, AAV vector genome was detected primarily in 
muscle tissues with undetectable distribution to other tissues (Figure 13B), consistent with 
the conclusion that reduction of serum bilirubin was due to muscle expression of functional 
UGT1A1.
The main goal of gene therapy for Crigler-Najjar syndrome is prevention of brain 
damage due to hyperbilirubinemia; complete normalization of serum bilirubin is not 
required to achieve this goal. By the IM delivery, the AAV vector did not result in complete 
normalization of serum bilirubin levels. On average, a 51% reduction of bilirubin levels 
was observed as compared with saline-injected control rats (Figure 8). Nevertheless, such 
reduction is clinically highly relevant because a 30-60% decrease would result in serum 
bilirubin levels below 20 mg/dl in most patients ( S t r a u s s  et al 2006). Patients with CN 
type II with levels below this threshold are not at risk for brain damage (A r ia s  et al 1969). 
Therefore, such a reduction would result in important clinical benefit in patients with CN 
type I. Given the limited invasiveness of AAV-mediated muscle-directed gene therapy, this 
approach may be useful also for patients with CN type II, thus avoiding long-term 
treatment with phenobarbital.
Muscle-directed gene therapy based on pDNA delivery was previously investigated 
in Gunn rats (JlA and D a n k o  2005a). In contrast with the pDNA study, we have 
demonstrated sustained correction and persistence of transgene expression after a single 
procedure of intramuscular injections. We also observed long-term correction of 
hyperbilirubinemia, whereas the study using pDNA detected immune elimination of
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transfected cells caused by the presence of anti-hUGTlAl antibodies and lymphocytic 
inflammation (JiA and Danko 2005a). Possible explanations for this difference include 
different vectors (AAV vs. pDNA), different routes of administration (intramuscular vs. 
limb perfusion), different promoters (MCK vs. CMV), different transgenes (rUGTlAl vs. 
hUGT 1A1), or a combination thereof.
A limitation o f muscle-directed gene therapy is the small number o f muscle fibers 
that are transduced after an IM injection. However, efficient delivery methods based on 
limb perfusion for AAV vector delivery have been developed to allow distribution o f the 
vector to a larger muscle mass (Arruda et al 2010; HAURIGOT et al. 2010). This approach 
may be potentially applicable also for CN type I to permit improved phenotypic correction 
by transduction o f a larger number o f muscle cells.
AAV vectors are non integrating vectors and loss of transgene expression will occur 
during cell division occurring in liver of growing patients. The onset of CN type I is in the 
neonatal period and, thus, liver-directed gene therapy performed at that time will likely 
results in loss of therapeutic effect. In contrast, as shown by both small and large animal 
studies (Sabatino et al 2007; Yue et al 2008), IM injections of AAV vectors in newborns 
result in long-term transgene expression in muscle, a tissue that can grow by cell fusion or 
by increase in protein content (Otto and Patel 2010). Therefore, the muscle is attractive 
as a target organ for gene therapy for CN type I. Moreover, newborns may not mount a 
vigorous immune response because of their immature immune system and thus muscle- 
directed gene therapy in the neonatal period may be an option for patients carrying disease 
mutations (e.g., nonsense mutations), who are more prone to develop anti-UGTlAl 
antibodies.
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In summary, IM injection of AAV provided an effective, simple, and safe gene 
delivery method that maintained long-term functional UGT1A1 in Gunn rat muscle and 
resulted in clinically relevant reduction of serum bilirubin levels for at least 1 year. The 
reduction of serum bilirubin was associated with increased excretion of bilirubin species in 
bile and urine. On the basis of the HPLC spectrum, as previously shown with ectopic 
expression of UGT1A1(Seppen et al 1997), non-physio logical bilirubin species were 
observed in Gunn rats receiving intramuscular injections of AAV vector, but their identities 
remain to be determined. Nevertheless, IM injections of AAV proved an effective, simple, 
and safe gene delivery method that maintained long-term functional UGT1A1 in Gunn rat 
muscle, and resulted in clinically relevant, long-term reduction of serum bilirubin levels.
6.2 Liver-directed gene therapy for CN type I with AAV2/8
Peripheral vein infusion of self-complementary AAV2/8 vector encoding FIX under 
the control of a liver-specific promoter resulted in FIX transgene expression at levels 
sufficient to improve the bleeding phenotype in patients with hemophilia B (N a th w a n i  et 
al. 2011b). Although immune-mediated clearance of AAV-transduced hepatocytes remains 
a concern and was eventually controlled with a short course of glucocorticoids, this clinical 
trial may pave the way towards applications of liver-directed gene therapy for a wide range 
of inborn errors of liver metabolism, including CN type I.
AAV vectors have several attributes that make them highly suitable for liver- 
directed gene therapy (N a th w a n i et al 2009). Studies in mice shown that at high vector 
doses, AAV2 can transduce up to 5-10% of the hepatocytes (N a k a i et al 2002) whereas 
the novel AAV serotypes, particularly AAV8, have improved hepatic transduction 
efficiency (D a v id o f f  et al 2005).
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A previous study investigated the efficiency of various AAV serotypes in the Gunn 
rats and found a reduction of serum bilirubin with all three AAV serotypes tested (AAV1, 
AAV6, and AAV8) (Seppen et al 2006). AAV1 was found to be the most effective and 
superior to AAV8. These results highlight species specificity as an important factor for 
AAV serotype transduction efficiency. Nevertheless, AAV8 remains the most attractive 
vectors considering the higher transduction efficiency achieved in nonhuman primate 
livers. This animal model is in fact considered more adequate to predict the human 
outcome. AAV8 is also attractive because compared to other serotypes it results in more 
rapid increase of transgene levels, less profound immune responses, and more limited 
biodistribution (Nathwani et al 2007). The previous study by Seppen et al. used AAV 
vectors with the ubiquitous CMV promoter. This promoter is not acceptable for human 
clinical trial because it results in higher likelihood of antibody response against the 
transgene product and it is also silenced over time in animal models (Pastore et al 1999). 
A critical factor in gene therapy is the requirement of sustaining expression of a therapeutic 
gene at an appropriate amount, but also expression in specific tissues. For this reason, 
promoter selection is particularly important.
During my thesis work, I compared two different expression cassettes within the 
AAV2/8 vector with the goal of identifying the most effective vector for liver-directed gene 
therapy of CN type I. Moreover, by comparing expression cassettes of different potency, I 
also investigated whether phenotypic correction is indeed affected by the transgene levels. 
Although it is predicted that being a non-cell autonomous disorder, higher transgene levels 
would result in improved phenotypic correction, this hypothesis has not been tested before.
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The expression cassettes I used for my studies had either the TBG or the LP1 
promoter. The TBG is a 54-kDa glycoprotein that is primarily active in hepatocytes and the 
TBG promoter has been frequently used to regulate various therapeutic genes in the liver 
(BlSH et al 2011; C a r r i l l o - C a r r a s c o  et al 2010; COTUGNO et al 2011; G a o  et al 
2002). Recent studies (Y a n  et al 2012) comparing relative activities of several constitutive 
(CMV, phosphoglycerate kinase, EFla,) and tissue-specific (apolipoprotein E, cytochrome 
P450 2E1) promoters have shown that the TBG promoter results in stable and high levels of 
transgene expression in vivo. The LP1 is a synthetic promoter that consists of the core 
domains from the human apolipoprotein hepatic control region and the human alpha-1- 
antitrypsin gene and has been used in several preclinical studies and in the hemophilia B 
AAV gene therapy trial (N a th w a n i et al 2007; N a th w a n i  et al 2006; N a th w a n i  et al. 
2011a).
The in vivo studies demonstrated that Gunn rats injected intravenously with the 
vector expressing the codon optimized hUGTlAl exhibited higher UGT1A1 levels when 
normalized for the vector genomes (Figure 18). Through a head-to-head comparison of the 
vectors encoding the wild-type hUGTlAl, I also observe higher transgene expression with 
the LP1 promoter compared to the TBG promoter (Figure 18). Importantly, the AAV8 
vector expressing the codon optimized hUGTlAl cDNA resulted in complete 
normalization of serum bilirubin levels at low vector doses (Figure 17). Clinical trials 
performed in hemophilia B patients using AAV vectors for liver-directed gene therapy have 
shown that there is a direct relationship between the AAV dose and the levels of 
hepatotoxicity as a consequence of an adaptive cellular immune response against the 
transduced hepatocytes (M a n n o  et al 2006; MlNGOZZl et al 2007; N a t h w a n i  et al 
2011b). Reducing the AAV dose may help to evade this immune response and therefore,
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vector harboring more potent expression cassette described herein may be useful for 
achieving therapeutic effect with lower vector doses.
Several studies have shown the consequences of codon usage on gene expression in 
mammalian cells (G u s ta f s s o n  et al. 2004). Gene expression in mammalian cells can be 
significantly enhanced by substituting rare codons with more frequent codons ( W e l l s  et al. 
1999; Z o lo tu k h in  et al. 1996). Each organism has its preferred choice of nucleotide usage 
to encode any particular amino acid. Besides variations between species, codon usage also 
differs among human tissue cells (P lo t k in  et al. 2004) and housekeeping genes are usually 
associated with higher GC-content. Differences in tissue specific expression of individual 
tRNA species and the relative abundance of tRNA-iso-acceptors strongly correlate with 
codon usage of genes highly expressed in specific tissues (D it tm a r  et al. 2006).
The codon optimization process is based on modification of the gene sequence 
according to the tRNA abundance in a specific species. We optimized the human sequence 
of hUGTlAl for the expression in Homo sapiens. The increase in expression we observed 
in the Gunn rats could be related to the similar codon usage between Homo sapiens and 
Rattus norvegicus (Figure 19).
In summary, our study shows that AAV2/8 vector with codon optimized UGT1A1 
gene under the control of the hepatocyte-specific LP1 promoter results in improved and 
sustained correction of hyperbilirubinemia in Gunn rats. Taken together, these data 
demonstrate the development of an optimal expression cassette for liver-directed gene 
therapy of CNI and form the preclinical basis for the development of a gene therapy trial 
for this severe disorder.
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Homo sapiens [gbpri]: 93487 CDS’s (40662582 codons)
fields: [triplet] [frequency: per thousand] ([number])
uuu 17.6(714295)
ouc 20.3(524692)
UUA 7.7(311551)
UUG 12.9(525655)
COO 13.2(536515)
cue 19.6(796635)
CUA 7.2(290751)
CUG 33.6(1611501)
AUU 16.0(650473)
a u c 20.5(546466)
AUA 7.5(304565)
AUG 22.0(596005)
GUU 11.0(445607)
GUC 14.5(555135)
GUA 7.1 (257712)
GUG 25.1(1143534)
UCU 15.2 (€16711) 
UCC 17.7(715592) 
UCA 12.2 (496448) 
UCG 5.4(179419)
CCU 17.5(713233) 
CCC 19.5(505620) 
CCA 16.9(655035) 
CCG 6.9(251570)
ACO 13.1(533609) 
ACC 15.9(765147) 
ACA 15.1(614523) 
ACG 6.1(246105)
GOT 15.4(750096) 
GCC 27.7(1127679) 
GCA 15.5(643471) 
GCG 7.4(299495)
UAU 12.2(495699) 
UAC 15.3(622407) 
OAA 1.0( 40255) 
UAG 0.5( 32109)
UGU 10.6(430311) 
OGC 12.6(513025) 
UGA 1.6( 63237) 
UGG 13.2(535595)
CAU 10.9(441711) CG’J 4.5(154609)
CAC 15.1(613713) CGC 10.4(423516)
CAA 12.3(501911) CGA 6.2(250760)
CAG 34.2(1391973) CGG 11.4(464455)
AAU 17.0(659701) 
AAC 19.1(776603) 
AAA 24.4(993621) 
AAG 31.9(1295565)
AGO 12.1(493429) 
AGC 19.5(791353) 
AGA 12.2(494652) 
AGG 12.0(456463)
GAU 21.5(555429) GGO 10.5(437126) 
GAC 25.1(1020595) GGC 22.2(903565) 
C-AA 29.0(1177632) GGA 16.5(669573) 
GAG 39.6(1609975) GGG 16.5(669765)
Coding GC 52.21%  1st letter GC 55.72% 2nd letter GC 42.54% 3rd letter GC 5S.55%
R attn s  norvegicus  [gbrod]: 15151 C D S ’s (6981149 codons)
fields: [triplet] [frequency, per thousand] ([number])
UUU 16.5(115495) UCU 14.5(103145) UAU 11.6( 50999) UGU 9. 5 ( 65415)
uuc 23.1(161565) UCC 17.5 (124290) UAC 17.1 (119192) UGC 11.9 ( 52751)
UUA 5 .9 ( 41454) UCA 10.9( 76435) UAA 0.6 ( 4473) UGA 1-2 ( 5137)
UUG 12.5 ( 59203) UCG 4 .4 ( 30455) UAG 0.5 ( 3637) UGG 13.2 ( 91955)
CUU 12.5( 57332) CCU 17.4 (121355) CAU 9.5 ( 66664) CGU 5.0 ( 34755)
cue 20.4(142093) CCC 15.0(125645) CAC 14.9(104027) CGC 9.5( 65456)
CUA 7.6 ( 52955) CCA 16.1(112364) CAA 11.1< 77366) CGA 6.5 ( 47207)
CUG 41.1 (256626) CCG 6.3 ( 43713) CAG 33.5(235764) CGG 10.9( 76123)
AUU 15.3 (106736) ACU 12.9( 90372) AAU 15.1(105212) AGU 11.5 ( 52659)
AUC 24.4(170096) ACC 19.7(137673) AAC 21.7 (151564) AGC 19.2(133954)
AUA 6.9( 45257) ACA 15.3 (106544) AAA 21.5 (150015) AGA 11.2( 77965)
AUG 23.1(161552) ACG 6.2 ( 43237) AAG 35.1(245259) AGG 11.S( 52391)
GUU 10.4 ( 72270) GCU 19.7(137491) GAU 20.9(146211) GGU 11.4 ( 79443)
GUC 16.2(113143) GCC 27.1(159524) GAC 25.0(195505) GGC 21.9(152552)
GUA 7.2 ( 5004S) GCA 15.6(109203) GAA 26.9(157510) GGA 16.6(115965)
GUG 30.0(209455) GCG 6.9 ( 47569) GAG 41.3 (255345) GGG 15.6(108657)
Coding GC 52.59%  1st letter GC 55.669 6 2nd letter GC 41.70%  3rd letter GC 60.40%
Figure 19. Codon usage in H o m o  s a p ie n s  and R a t tu s  n o r v e g ic u s .
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